All In Biotech

Drug Trial Radar · NCT07376629

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

A Phase II Study of HB0025 in Combination With Nab-Paclitaxel as First Line Therapy for Unresectable, Locally Advanced or Metastatic Triple-negative Breast Cancer.

Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 14, 2025

Primary completion

Jan 15, 2027

Study completion Jan 15, 2027

Sponsor

Lead sponsor
Huabo Biopharm Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of HB0025 administered with chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).

Conditions

  • TNBC

Interventions

  • HB0025 20 mg/kg plus nab-paclitaxelDrug

    HB0025 20 mg/kg

  • HB0025 10 mg/kg plus nab-paclitaxelDrug

    HB0025 10 mg/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The safety and tolerability measures: Incidence,correlation, and severity of adverse events graded according to NCI CTCAE v5.0.Time frame: From first dose to the time of the disease progression, intolerable toxicity, initiation of new antitumor therapy, loss to follow-up, death, withdrawal of study, completion of 2-year treatment of HB0025, or other reasons, whichever comes first.

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Anyang Cancer Hospital

    Anyang, China

  • Xiangya Hospital Central South University

    Changsha, China

  • Sichuan Cancer Hospital

    Chengdu, China

  • Fujian Cancer Hospital

    Fujian, China

  • Guangdong Provincial People's Hospital

    Guangdong, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Anhui Provincial Hospital

    Hefei, China

  • The First Hospital of Jilin University

    Jilin City, China

  • Affiliated Hospital of Jining Medical University

    Jining, China

  • Linyi Cancer Hospital

    Linyi, China

  • Jiangsu Province Hospital

    Nanjing, China

  • Shandong Cancer Hospital

    Shandong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Shanxi Cancer Hospital

    Shanxi, China

  • Liaoning Cancer Hospital

    Shengyang, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, China

  • Tianjin Cancer Hospital

    Tianjing, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China

  • Xuzhou Central Hospital

    Xuzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.